Docetaxel, Androgen Ablation, and External-Beam Radiation Therapy in Patients With High-Risk Localized Prostate Cancer
Status:
Completed
Trial end date:
2012-08-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the
growth of tumor cells, either by killing the cells or by stopping them from dividing.
Androgens can cause the growth of prostate cancer cells. Antihormone therapy, such as
leuprolide, may lessen the amount of androgens made by the body. Radiation therapy uses high
energy x-rays to kill tumor cells. Giving docetaxel together with androgen ablation therapy
and external-beam radiation therapy may kill more tumor cells.
PURPOSE: This phase I/II trial is studying the side effects and best dose of docetaxel when
given together with androgen ablation therapy and external-beam radiation therapy and to see
how well they work in treating patients with high-risk localized prostate cancer.